Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001193125-17-342616
Filing Date
2017-11-14
Accepted
2017-11-14 16:29:33
Documents
16

Document Format Files

Seq Description Document Type Size
1 424B3 d486549d424b3.htm 424B3 1284263
2 GRAPHIC g486549g02q86.jpg GRAPHIC 448216
3 GRAPHIC g486549g02x90.jpg GRAPHIC 114983
4 GRAPHIC g486549g08p69.jpg GRAPHIC 69216
5 GRAPHIC g486549g13l34.jpg GRAPHIC 105972
6 GRAPHIC g486549g16o08.jpg GRAPHIC 113289
7 GRAPHIC g486549g30y40.jpg GRAPHIC 23405
8 GRAPHIC g486549g37j02.jpg GRAPHIC 112212
9 GRAPHIC g486549g42f86.jpg GRAPHIC 108685
10 GRAPHIC g486549g49p57.jpg GRAPHIC 76445
11 GRAPHIC g486549g61b08.jpg GRAPHIC 101939
12 GRAPHIC g486549g64t03.jpg GRAPHIC 67383
13 GRAPHIC g486549g70w78.jpg GRAPHIC 107641
14 GRAPHIC g486549g82r79.jpg GRAPHIC 204670
15 GRAPHIC g486549g85w22.jpg GRAPHIC 146068
16 GRAPHIC g486549g98r06.jpg GRAPHIC 73294
  Complete submission text file 0001193125-17-342616.txt   3866582
Mailing Address 100 CONGRESS AVENUE SUITE 2000 AUSTIN TX 78701
Business Address 100 CONGRESS AVENUE SUITE 2000 AUSTIN TX 78701 512-708-0155
Genprex, Inc. (Filer) CIK: 0001595248 (see all company filings)

EIN.: 900772347 | Fiscal Year End: 1213
Type: 424B3 | Act: 33 | File No.: 333-219386 | Film No.: 171202036
SIC: 2834 Pharmaceutical Preparations